PepGen's technology improves the delivery of a therapy to more tissue types and the clinical-stage biotech plans to use its IPO cash to continue developing its lead program for Duchenne muscular dystrophy. Meanwhile, eye products giant Bausch + Lomb returned to the public markets as a standalone company. Both the PepGen and Bausch + Lomb IPOs priced below their respective price ranges.
MedCity INVEST PharmaTech 2022 is a program dedicated to exploring the next chapter of the biopharma industry. Discussions will explore how pharma companies leverage digital innovations to achieve greater success and transform the lives of patients.
The Allston, Massachusetts-based health tech startup is looking to help people on Medicaid not only quit smoking but also make other behavioral changes that will improve their overall health. Its platform offers everything from financial incentives to personalized coaching.
Hospitals already have a tool at their disposal that addresses affordability for their patients. Financial assistance programs can prevent many patients from having accounts sent to collections in the first place.
INVEST PharmaTech Pitch Perfect virtual conference July 26 will give startups the opportunity to present their approaches to clinical trial innovation to a team of investor judges. Apply today!
No comments